CNEN

Welcome to Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd.!

Search

Copyright:  Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd.!   京ICP备19006400号-1​     Powered by 300.cn

美科

Links:

A number of Class A Hospitals in China

2018年8月,九芝堂美科与北京天坛医院签订《干细胞临床研究基地共建协议》。双方就干细胞治疗疾病感兴趣的适应症上优先开展干细胞临床合作,并且天坛医院专家作为美科新药注册申请的“干细胞治疗脑卒中后遗症”及“干细胞治疗阿尔茨海默症”的主要研究者,双方共同开展药物临床试验。未来,双方将就干细胞药物的药效方面开展更多的研究,进一步开发干细胞在其他适应症上的应用。
Affiliate classification
没有此类产品
Details

Beijing Tiantan Hospital affiliated to Capital Medical University

Beijing Tiantan Hospital affiliated to Capital Medical University is Class 3A comprehensive teaching hospital specializing in neurosurgery, and one of the three neurosurgical research centers in the world. Tiantan Hospital is home to China National Clinical Research Center for Neurological Diseases, China’s biggest clinical research platform in the field of neurological diseases.

Jiuzhitang Maker and Tiantan Hospital signed the Agreement on Co-Construction of A Stem Cells Clinical Research Base in 2018. The two sides will continuously push forward stem cell-related clinical studies under this agreement.

On January 12, 2021, China’s first phase I/IIa clinical trial (ASSIST) using an imported stem cell product to treat ischemic stroke was officially launched. This is the first study on stem cell therapy for cerebrovascular disease that will be run in accordance with the current Good Clinical Practice since the country started to regulate stem cells as a drug. It bears great significance to promoting the clinical application of stem cells in treatment of cerebrovascular diseases and bringing about changes to the regulation system on stem cell products.

 

首都医科大学附属北京天坛医院

 

The 2nd Affiliated Hospital of Harbin Medical University

With the lot area being 500,000 m2 and floor area being 530,000 m2, the 2nd Affiliated Hospital of Harbin Medical University has 1 outpatient department, 11 inpatient departments and 4 specialized hospitals dedicated to treatment of rheumatism, cardiovascular disorders, diseases involving the five sense organs and diabetes.

In May 2020, by signing a Cooperation Agreement, Jiuzhitang Maker and the 2nd Affiliated Hospital of Harbin Medical University agreed to jointly apply for a filed clinical study on stem cells with National Health Commission.

 

 

Corresponding parameter set not found, please add it in property template of background
暂未实现,敬请期待
暂未实现,敬请期待
Previous article